ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...
There are two types of inflammation: acute and chronic. Acute inflammation is the kind that lasts a few hours, days, or weeks, and it’s helpful to healing. It’s your immune system’s response when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback